K2 Principal Fund, L.P. Ironwood Pharmaceuticals Inc Call Options Transaction History
K2 Principal Fund, L.P.
- $210 Million
- Q3 2024
Call Options
2 transactions
Others Institutions Holding IRWD
# of Institutions
237Shares Held
162MCall Options Held
11.2MPut Options Held
9.1K-
Black Rock Inc. New York, NY22.9MShares$102 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA22MShares$98.1 Million0.0% of portfolio
-
Sarissa Capital Management LP Greenwich, CT16.4MShares$72.9 Million16.75% of portfolio
-
Pacer Advisors, Inc. Malvern, PA11.3MShares$50.2 Million0.11% of portfolio
-
State Street Corp Boston, MA9.92MShares$44.1 Million0.0% of portfolio
About IRONWOOD PHARMACEUTICALS INC
- Ticker IRWD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 153,231,008
- Market Cap $682M
- Description
- Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...